Therefore, we hypothesized that the B7x-mediated reduction of CTLA-4 would make tumor-infiltrating Tregs poorer targets for immunotherapy and thus reduce the efficacy of anti-CTLA-4 therapy. This evidence concerns the gene VTCN1 and neoplasm.